Key Drivers
- Quarterly Reversal
- High Leverage
- Cash Burn
AIAI Summary
MNKD is evolving into a diversified specialty-pharma platform, but the investable catalyst is not revenue growth alone—it is proof that ReadyFlow and pediatric Afrezza can generate recurring sales, positive free cash flow, and improved debt-service coverage against $565M of debt. Investors should remain cautious until launch traction translates into operating leverage rather than higher expenses and continued cash burn.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Quarterly Reversal
- •High Leverage
- •Cash Burn
MNKD's strong 2025 profitability has deteriorated sharply in 2026, with losses, cash burn, heavy debt, and negative equity outweighing its liquidity and gross-margin strengths.
Price Behavior
Key Price Behavior Insights:
- •Sustained downtrend
- •Support under pressure
- •Oversold rebound
MNKD is in a bearish last-month downtrend, with $3.54–$3.56 support at risk and an oversold bounce needing a reclaim of $3.75–$3.79 to improve momentum.
Selling accelerated after the $4.16 high on 2026-09-08
Sentiment & News
Key News Insights:
- •Pediatric Afrezza Expansion
- •ReadyFlow Demand
- •GLP-1 Partnership
MannKind is advancing growth through pediatric Afrezza, FUROSCIX ReadyFlow uptake, MNKD-201 data, and a GLP-1 partnership, though collaboration-related share pressure highlights execution risk.
The updates strengthen MannKind's pipeline and commercialization outlook, but near-term share performance may remain sensitive to partnership execution
Similar Companies in Healthcare
Other companies in the same sector with AI ratings